The Latest Lipid Guidelines:

Goals

Evolution of Lipid Guidelines

Evolution of Lipid Guidelines (cont)

Evolution of Lipid Guidelines (cont)

Lowering LDL-C Reduces Risk for Major CV Events

IMPROVE-IT: Benefit With Ezetimibe

FOURIER: Profound LDL-C Reductions

FOURIER: CV Outcomes

Evolution of Lipid Guidelines (cont)

FOURIER: LDL Cholesterol In patients with baseline LDL-C≤70 mg/dL

FOURIER: Clinical Outcomes In patients with baseline LDL-C<70 mg/dL

FOURIER Analysis: Time-Weighted Median LDL-Cholesterol Concentrations

FOURIER Analysis: CV Death, MI, Stroke

LDL-C: Target, Goals, and Thresholds for Nonstatin Therapy

Evolution of Lipid Guidelines (cont)

Non-HDL-C and ApoB Considered Important Thresholds for ASCVD (ODYSSEY)

2017 ACC EXPERT CONSENSUS DECISION PATHWAY

Examples of High-, Moderate-, and Low-Intensity Statin Therapy

Algorithm for Stepwise Approach in Treatment of Heterozygous FH and Clinical ASCVD with PCSK9 Inhibitors

FOURIER: Safety Events By Achieved LDL-C At 4 Weeks After Randomization

FOURIER: Safety Events By Achieved LDL-C At 4 Weeks After Randomization (cont)

FOURIER: New-Onset Diabetes

FOURIER: Glycemic Parameters

Considerations Prior to Starting PCSK9 Inhibitors

Take Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)